<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T0005" orientation="landscape" position="float">
 <label>Table 5</label>
 <caption>
  <p>Common adverse reactions to antiretroviral and antitubercular drugs</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Toxicity</th>
    <th rowspan="1" colspan="1">Antiretroviral</th>
    <th rowspan="1" colspan="1">Antitubercular</th>
    <th rowspan="1" colspan="1">Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">Peripheral neuropathy</td>
    <td rowspan="1" colspan="1">D4T, ddI, ddC</td>
    <td rowspan="1" colspan="1">Lzd, Cs, H, Sm, Km, Am, Eto/Pto, E</td>
    <td rowspan="1" colspan="1">● Avoid use of D4T, ddI, and ddC in combination with Cs or Lzd because of increased peripheral neuropathy
     <break/>● If these agents must be used and peripheral neuropathy develops, replace the ART with a less neurotoxic agent
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Central nervous system (CNS) toxicity</td>
    <td rowspan="1" colspan="1">Efv</td>
    <td rowspan="1" colspan="1">Cs, H, Eto/Pto,
     <break/>Ofx, Lfx, Mfx, Lzd
    </td>
    <td rowspan="1" colspan="1">● Efv has a high rate of adverse CNS drug reactions (confusion, impaired concentration, depersonalization, abnormal dreams, insomnia, and dizziness) in the first 2–3 weeks, which typically resolve on their own
     <break/>● If these effects do not resolve on their own, consider substitution of the agent
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Depression/psychosis</td>
    <td rowspan="1" colspan="1">Efv</td>
    <td rowspan="1" colspan="1">Cs, Tzd, Ofx, Lfx, Mfx, H, Eto/Pto</td>
    <td rowspan="1" colspan="1">● Severe depression can be seen in 2.4% of patients receiving Efv
     <break/>● Consider substituting for Efv if severe depression develops
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Headache</td>
    <td rowspan="1" colspan="1">Azt, Efv,
     <break/>all integrase inhibitors
    </td>
    <td rowspan="1" colspan="1">Cs, Bdq</td>
    <td rowspan="1" colspan="1">● Rule out more serious causes of headache, such as bacterial meningitis, cryptococcal meningitis, CNS toxoplasmosis
     <break/>● Use of analgesics (ibuprofen, paracetamol) and good hydration may help.
     <break/>● Headache secondary to Azt, Efv, and Cs is usually self-limited
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Nausea and vomiting</td>
    <td rowspan="1" colspan="1">Rtv, D4T,
     <break/>Nvp, Rgv
    </td>
    <td rowspan="1" colspan="1">Eto/Pto, PAS, H, E, Z, Bdq</td>
    <td rowspan="1" colspan="1">● Nausea and vomiting are common adverse drug reactions and can be managed
     <break/>● Persistent vomiting and abdominal pain may be a result of developing lactic acidosis and/or hepatitis secondary to medications
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Abdominal pain</td>
    <td rowspan="1" colspan="1">All ART treatments have been associated with abdominal pain</td>
    <td rowspan="1" colspan="1">Cfz, Eto/Pto, PAS</td>
    <td rowspan="1" colspan="1">● Abdominal pain is a common adverse drug reaction and often benign
     <break/>● Abdominal pain may be an early symptom of severe adverse drug reactions, such as pancreatitis, hepatitis, or lactic acidosis
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Pancreatitis</td>
    <td rowspan="1" colspan="1">D4T, ddI, ddC</td>
    <td rowspan="1" colspan="1">Lzd</td>
    <td rowspan="1" colspan="1">● Avoid use of these agents together
     <break/>● If an agent causes pancreatitis, suspend it permanently and do not use any pancreatitis-producing ART (D4T, ddI, or ddC) in future.
     <break/>● Also consider gallstones or alcohol as a potential cause of pancreatitis
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Diarrhea</td>
    <td rowspan="1" colspan="1">All protease inhibitors, ddI (buffered formula), Rgv</td>
    <td rowspan="1" colspan="1">Eto/Pto, PAS,
     <break/>Ofx, Lfx, Mfx
    </td>
    <td rowspan="1" colspan="1">● Diarrhea is a common adverse drug reaction
     <break/>● Also consider opportunistic infections as a cause of diarrhea, or 
     <italic>Clostridium difficile</italic> (a cause of pseudomembranous colitis)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hepatotoxicity</td>
    <td rowspan="1" colspan="1">Nvp, Efv, all PIs, all NsRTIs, all integrase inhibitors, maraviroc</td>
    <td rowspan="1" colspan="1">H, R, E, Z, PAS, Eto/Pto, Ofx, Lfx, Mfx, Bdq</td>
    <td rowspan="1" colspan="1">● Also consider Tmp-Smx as a cause of hepatotoxicity if the patient is receiving this medication
     <break/>● Also rule out viral etiologies, such as cause of hepatitis (hepatitis A, B, C, and CMV)
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Skin rash</td>
    <td rowspan="1" colspan="1">Abc, Nvp, Efv, D4T, maraviroc</td>
    <td rowspan="1" colspan="1">H, R, Z, PAS, Am, Km, Ofx, Lfx, Mfx, Amx-Clv, T</td>
    <td rowspan="1" colspan="1">● Do not rechallenge with Abc (can result in life-threatening anaphylaxis)
     <break/>● Do not rechallenge with an agent that causes Stevens–Johnson syndrome
     <break/>● Also consider Tmp-Smx as a cause of skin rash if the patient is receiving this medication
     <break/>● T is contraindicated in HIV because of life-threatening rash
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Lactic acidosis</td>
    <td rowspan="1" colspan="1">D4T, ddI, Azt, 3TC</td>
    <td rowspan="1" colspan="1">Lzd</td>
    <td rowspan="1" colspan="1">● If an agent causes lactic acidosis, replace it with an agent less likely to cause lactic acidosis</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Nephrotoxicity</td>
    <td rowspan="1" colspan="1">TDF</td>
    <td rowspan="1" colspan="1">Sm, Km,
     <break/>Am, Cm, Lfx
    </td>
    <td rowspan="1" colspan="1">● TDF may cause renal injury with features characteristic of Fanconi syndrome, hypophosphatemia, hypouricemia, proteinuria, normoglycemic glycosuria, and in some cases acute renal failure
     <break/>● Use TDF with caution in patients receiving aminoglycosides or Cm and Lfx
     <break/>● Mfx should be preferred when ART contains TDF
     <break/>● Frequent creatinine and electrolyte monitoring every 1 to 3 weeks is recommended
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Nephrolithiasis</td>
    <td rowspan="1" colspan="1">Idv</td>
    <td rowspan="1" colspan="1">None</td>
    <td rowspan="1" colspan="1">● No overlapping toxicities regarding nephrolithiasis have been documented between ART and anti-TB medications
     <break/>● Adequate hydration prevents nephrolithiasis in patients taking Idv
     <break/>● If nephrolithiasis develops while on Idv, substitute with another PI if possible
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Electrolyte disturbances</td>
    <td rowspan="1" colspan="1">TDF</td>
    <td rowspan="1" colspan="1">Cm, Sm, Km,
     <break/>Am
    </td>
    <td rowspan="1" colspan="1">● Diarrhea and/or vomiting can contribute to electrolyte disturbances
     <break/>● Even without concurrent use of TDF, HIV-infected patients have increased risk of both renal toxicity and electrolyte disturbances secondary to aminoglycosides and Cm
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Bone-marrow suppression</td>
    <td rowspan="1" colspan="1">Azt</td>
    <td rowspan="1" colspan="1">Lzd, R, Rfb, H</td>
    <td rowspan="1" colspan="1">● Monitor blood counts regularly
     <break/>● Replace Azt if bone-marrow suppression develops
     <break/>● Consider suspension of Lzd
     <break/>● Also consider Tmp-Smx as a cause if the patient is receiving this medication
     <break/>● Consider adding folinic acid supplements, especially if receiving Tmp-Smx
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Optic neuritis</td>
    <td rowspan="1" colspan="1">ddI</td>
    <td rowspan="1" colspan="1">E,
     <break/>Eto/Pto (rare)
    </td>
    <td rowspan="1" colspan="1">● Suspend agent responsible for optic neuritis permanently
     <break/>● Replace with an agent that does not cause optic neuritis
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hyperlipidemia</td>
    <td rowspan="1" colspan="1">PIs, Efv</td>
    <td rowspan="1" colspan="1">None</td>
    <td rowspan="1" colspan="1">● No overlapping toxicities regarding hyperlipidemia have been documented between ART and anti-TB medications</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Lipodystrophy</td>
    <td rowspan="1" colspan="1">NRTIs (especially D4T and ddI)</td>
    <td rowspan="1" colspan="1">None</td>
    <td rowspan="1" colspan="1">● No overlapping toxicities regarding lipodystrophy have been documented between ART and anti-TB medications</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Dysglycemia
     <break/>(disturbed blood-sugar regulation)
    </td>
    <td rowspan="1" colspan="1">PIs</td>
    <td rowspan="1" colspan="1">Gfx, Eto/Pto</td>
    <td rowspan="1" colspan="1">● PIs tend to cause insulin resistance and hyperglycemia
     <break/>● Eto/Pto tend to make insulin control in diabetics more difficult and can result in hypoglycemia and poor glucose regulation
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Hypothyroidism</td>
    <td rowspan="1" colspan="1">D4T</td>
    <td rowspan="1" colspan="1">Eto/Pto, PAS</td>
    <td rowspan="1" colspan="1">● There is potential for overlying toxicity, but evidence is mixed
     <break/>● Several studies show subclinical hypothyroidism associated with ART, particularly d4T
     <break/>● PAS and Eto/Pto, especially in combination, can commonly cause hypothyroidism
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Myopathy
     <break/>rhabdomyolysis
    </td>
    <td rowspan="1" colspan="1">Azt, Rgv</td>
    <td rowspan="1" colspan="1">E, Z</td>
    <td rowspan="1" colspan="1">● Clinical correlation to rule out offending drug
     <break/>● Monitoring with creatine phosphokinase
     <break/>● Thorough clinical evaluation to rule out HIV-associated myopathy
     <break/>● Muscle biopsy can be performed
     <break/>● Azt-associated mitochondrial myopathy
    </td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">QT prolongation</td>
    <td rowspan="1" colspan="1">Efv, All PIs</td>
    <td rowspan="1" colspan="1">Lfx, Mfx, Cfz, Bdq, Dlm</td>
    <td rowspan="1" colspan="1">● Close monitoring to be done by ECG
     <break/>● Mfx is more commonly associated with QT prolongation
     <break/>● Lfx preferred over Mfx
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
